Despite Neurocrine's Epilepsy Drug Missing Primary Goal In Pediatric Trial, Analyst Sees Strong Growth

  • Neurocrine Biosciences Inc's NBIX NBI-827104 did not meet its primary endpoint in the Phase 2 STEAMBOAT study compared to placebo in pediatric patients with epileptic encephalopathy with continuous spike-and-wave during sleep (EE-CSWS). 
  • The primary endpoint was a reduction from baseline in the spike-wave index (SWI) ratio when measured after six weeks of study treatment. 
  • Related: Neurocrine Biosciences Buys UK-Based Hormone Therapy Player.
  • The SWI measures the percentage of sleep affected by epileptic activity.
  • NBI-827104, an investigational brain-penetrating T-type calcium channel blocker, was generally well tolerated.
  • William Blair's Take: Despite this disappointing update, the analyst views Neurocrine as a strong growth performer with significant potential in its growing Ingrezza franchise. 
  • This miss adds to a slew of recent pipeline misses. Still, William Blair believes there is much to like about specific assets remaining. The analyst reiterates Outperform rating on Neurocrine.
  • Price Action: NBIX shares closed 4.54% lower at $114.75 during after-hours trading on Tuesday.
Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: Analyst ColorBiotechNewsHealth CarePre-Market OutlookAnalyst RatingsMoversTrading IdeasGeneralBiotechnologyBriefsHealth Carewhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!